Koichi Azuma

14.2k citations

270 papers · 6.3k · 2 hit papers · h-index 42

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Hepatology top 1%
- Hepatitis C virus research

Papers in

Pulmonary and Respiratory Medicine 123
- Lung Cancer Treatments and Mutations 110
- Lung Cancer Diagnosis and Treatment 25
Oncology 110
- Cancer Immunotherapy and Biomarkers 38
- Lung Cancer Research Studies 38
- Colorectal Cancer Treatments and Studies 26
- HER2/EGFR in Cancer Research 15

Co-authors: Akihiko Kawahara (60 shared papers)Tomoaki Hoshino (64 shared papers)Satoshi Hattori (27 shared papers)Masayoshi Kage (26 shared papers)Isamu Okamoto (46 shared papers)Yoichi Nakanishi (19 shared papers)Shinzo Takamori (13 shared papers)Eiji Iwama (13 shared papers)
Journals: Journal of Clinical Oncology (31 papers)Journal of Thoracic Oncology (15 papers)Annals of Oncology (13 papers)Lung Cancer (9 papers)Oncotarget (8 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Koichi Azuma

256 papers receiving 6.3k citations

Koichi Azuma's Hit Papers

align trajectories log scale

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer 2015 · 370 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Clinical Cancer Research
2014 Annals of Oncology

Peers

Countries citing papers authored by Koichi Azuma

Since Specialization

Citations

This map shows the geographic impact of Koichi Azuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koichi Azuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koichi Azuma more than expected).

Fields of papers citing papers by Koichi Azuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koichi Azuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koichi Azuma. The network helps show where Koichi Azuma may publish in the future.

Co-authors

The 25 scholars most cited alongside Koichi Azuma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Koichi Azuma Line = papers co-authored together Koichi Azuma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 270 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer Annals of Oncology ·Koichi Azuma, Keiichi Ota, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Takeshi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, M. Kage, Tomoaki Hoshino, Yoichi Nakanishi, Isamu Okamoto Hit paper breakdown →	2014	528
2	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer Clinical Cancer Research ·Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, Masayoshi Kage, Tomoaki Hoshino, Yoichi Nakanishi, Isamu Okamoto Hit paper breakdown →	2015	370
3	Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy European Journal of Cancer ·Takaaki Tokito, Koichi Azuma, Akihiko Kawahara, Hidenobu Ishii, Kazuhiko Yamada, Norikazu Matsuo, Takashi Kinoshita, Naohisa Mizukami, Hirofumi Ono, Masayoshi Kage, Tomoaki Hoshino	2016	166
4	Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Journal of Thoracic Oncology ·Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino	2014	155
5	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor JAMA Oncology ·Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto	2021	125
6	Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis Clinical Cancer Research ·Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashihara, Hisamichi Aizawa, Yuji Basaki, Michihiko Kuwano, Masayoshi Kage, Tetsuya Mitsudomi, Mayumi Ono	2010	99
7	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study Journal of Hepatology ·Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Toshihiro Maruyama, Yuichi Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi	2012	98
8	Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study Journal of Thoracic Oncology ·Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Takehito Shukuya, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Daichi Fujimoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi	2022	96
9	FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor Oncotarget ·Koichi Azuma, Akihiko Kawahara, Kahori Sonoda, Kazutaka Nakashima, Kousuke Tashiro, Kosuke Watari, Hiroto Izumi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono, Tomoaki Hoshino	2014	92
10	Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapy Cancer Science ·Koichi Azuma, Yoshihiro Komohara, Tetsuro Sasada, Yasuhiro Terazaki, Jirō Ikeda, Tomoaki Hoshino, Kyogo Itoh, Akira Yamada, Hisamichi Aizawa	2007	83
11	Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages PLoS ONE ·Kosuke Watari, Tomohiro Shibata, Akihiko Kawahara, Ken-ichi Sata, Hiroshi Nabeshima, Ai Shinoda, Hideyuki Abe, Koichi Azuma, Yûichi Murakami, Hiroto Izumi, Takashi Takahashi, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono	2014	79
12	Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment Alimentary Pharmacology & Therapeutics ·Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, A. Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, T. Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi	2017	78
13	Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel Lung Cancer ·Koichi Azuma, Tetsuro Sasada, Akihiko Kawahara, Sinzo Takamori, Satoshi Hattori, Jirō Ikeda, Kyogo Itoh, Akira Yamada, Masayoshi Kage, Michihiko Kuwano, Hisamichi Aizawa	2008	73
14	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients Scientific Reports ·Norikazu Matsuo, Koichi Azuma, Kazuko Sakai, Satoshi Hattori, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Takashi Kinoshita, Kazuhiko Yamada, Kazuto Nishio, Tomoaki Hoshino	2016	73
15	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity Clinical Cancer Research ·Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi, Takuma Irie, Katsunori Tatsugami, Tomoaki Hoshino, Masatoshi Eto, Hiroyoshi Nishikawa	2019	72
16	Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations Annals of Oncology ·Eiji Iwama, Kazuko Sakai, Koichi Azuma, Takeshi Harada, Daijiro Harada, Kaname Nosaki, K. Hotta, F. Ohyanagi, Takayasu Kurata, Tatsuro Fukuhara, Hiroaki Akamatsu, Kōichi Goto, Takayuki Shimose, Junji Kishimoto, Y. Nakanishi, Kazuto Nishio, Isamu Okamoto	2016	69
17	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) Oncotarget ·Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Koichi Azuma, Toyoaki Hida, Masataka Hirabayashi, Tetsuya Oguri, Hiroshi Tanaka, Noriyuki Ebi, Toshiyuki Sawa, Akihiro Bessho, Motoko Tachihara, Hiroaki Akamatsu, Shuji Bandoh, Daisuke Himeji, Tatsuo Ohira, Mototsugu Shimokawa, Yoichi Nakanishi, Kazuhiko Nakagawa, Kazuto Nishio	2016	65
18	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples Oncotarget ·Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Akihiko Kawahara, Kazuhiko Yamada, Takaaki Tokito, Isamu Okamoto, Kazuto Nishio, Tomoaki Hoshino	2015	65
19	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non–small cell lung cancer harboring EGFR mutations Oncotarget ·Kentaro Tanaka, Kaname Nosaki, Kohei Otsubo, Koichi Azuma, Shinya Sakata, Hiroshi Ouchi, Ryotaro Morinaga, Hiroshi Wataya, Akiko Fujii, Noriaki Nakagaki, Nobuko Tsuruta, Masafumi Takeshita, Eiji Iwama, Taishi Harada, Yoichi Nakanishi, Isamu Okamoto	2017	63
20	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer Molecular Cancer Therapeutics ·Yoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, Young Hak Kim, Yosuke Togashi, Yuichi Sesumi, Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa, Toshiki Takemoto, Kazuto Nishio, Tetsuya Mitsudomi	2016	59

About Koichi Azuma

Koichi Azuma is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Hepatology and Immunology, having authored 270 papers that have together received 6.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (110 papers), Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Research Studies (38 papers), Colorectal Cancer Treatments and Studies (26 papers), Lung Cancer Diagnosis and Treatment (25 papers), Hepatitis C virus research (23 papers), HER2/EGFR in Cancer Research (15 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Oncology (2.5k citations), Hepatology (583 citations), Pulmonary and Respiratory Medicine (2.4k citations), Cancer Research (650 citations) and Immunology (674 citations). Koichi Azuma has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Akihiko Kawahara, Tomoaki Hoshino, Satoshi Hattori, Masayoshi Kage, Isamu Okamoto, Yoichi Nakanishi, Shinzo Takamori, Eiji Iwama, Hidenobu Ishii and Kazuhiko Yamada. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Koichi Azuma

Impact in

Papers in i

In The Last Decade

Koichi Azuma

Koichi Azuma's Hit Papers

Peers

Countries citing papers authored by Koichi Azuma

Fields of papers citing papers by Koichi Azuma

All Works

About Koichi Azuma

Explore authors with similar magnitude of impact

Papers in